Etiology of angiogenesis inhibition-related hypertension

Research output: Contribution to journalArticleAcademicpeer-review

34 Citations (Scopus)

Abstract

Angiogenesis inhibition, targeting vascular endothelial growth factor (VEGF) or its receptors, is an established treatment for solid tumors. A common side effect of this treatment is the development of sometimes severe hypertension. This hypertension is associated with a decrease in nitric oxide production, activation of the endothelin-signaling pathway and renin suppression. The mechanism underlying activation of the endothelin-signaling pathway is not fully understood. Both activation of endothelial cells and disinhibition of the VEGF-induced suppression of endothelin production by endothelial cells may be involved. The development of hypertension can be a reason to discontinue the angiogenesis inhibitor, thereby compromising anticancer treatment, but possibly is also a biomarker for a favorable antitumor response.
Original languageUndefined/Unknown
Pages (from-to)7-13
Number of pages7
JournalCurrent Opinion in Pharmacology
Volume21
DOIs
Publication statusPublished - 2015

Cite this